Select Publications

1. Chaudagar K*, Rameshbabu S* (*equal contribution), Mei S, Hirz T, Hu Y, Argulian A, Labadie B, Desai K, Grimaldo S, Kahramangil D, Nair R, D’Souza S, Zhou D, Li M, Doughan F, Chen R, Shafran J, Loyd M, Xia Z, Sykes D, Moran A, Patnaik A. Androgen Blockade in Macrophages Primes NLRP3-driven Tumor Phagocytosis.Under Revision. https://www.biorxiv.org/content/10.1101/2023.09.15.557996v2.

2. Chaudagar K, Hieromnimon H, Kelley A, Labadie B, Shafran J, Rameshbabu S, Drovetsky C, Bynoe K, Solanki A, Markiewicz E, Fan X, Loda M, Patnaik A. Suppression of tumor cell lactate-generating signaling pathways eradicates murine PTEN/p53-deficient aggressive-variant prostate cancer via macrophage phagocytosis. Clin. Cancer Res. 2023; doi: https://doi.org/10.1158/1078-0432.ccr-23-1441. PMID: 37721526. PMCID: PMC10841690.

3. Chaudagar K, Hieromnimon H, Khurana R, Labadie B, Hirz T, Mei S, Hasan R, Shafran J, Kelley A, Apostolov E, El-Aryani G, Harvey K, Rameshbabu S, Loyd M, Bynoe K, Drovetsky C, Solanki A, Markiewicz E, Zamora M, Fan X, Schürer S, Swarbrick A, Sykes D, Patnaik A. Reversal of lactate and PD-1-mediated macrophage immunosuppression controls growth of PTEN/p53-deficient prostate cancer. Clin. Cancer Res. 2023; 29(10):1952–1968. PMID: 36862086.

4. Olson B, Chaudagar K, Bao R, Sharma Saha S, Hong C, Marguerite Li, Srikrishnan Rameshbabu, Raymond Chen, Alison Thomas, Patnaik A. BET inhibition sensitizes immunologically-cold Rb-deficient prostate cancer to immune checkpoint blockade. Mol. Cancer Ther. 2023; 22 (6):751–764. PMID: 37014264. 

5. Abida W, Campbell D, Patnaik A, Bryce A, Shapiro J, Bambury R, Zhang J, Burke M, Castellano G, Font A, Ganju V, Hardy-Bessard A-C, McDermott R, Sautois B, Spaeth D, Voog E, Piulats J, Pintus E, Ryan C, Merseburger A, Daugaard G, Heidenreich A, Fizazi K, Loehr A, Despain D, Simmons A, Dowson M, GoJ, Watkins S, PhD, Chowdhury S. Rucaparib for the Treatment of Metastatic Castration-Resistant Prostate Cancer Associated With a DNA Damage Repair Gene Alteration: Final Results From the Phase 2 TRITON2 Study. Eur. Urol. 2023; DOI: 10.1016/j.eururo.2022.09.010. PMID: 36243543. 

6. Reizine N, Socco S, Weng E, Atueyi U, Mehta V, Patnaik A. Utilization of NGS in conjunction with IHC to predict exceptional response to combination immune checkpoint therapy in a heavily pre-treated patient with castration-resistant prostate cancer. JCO Precis Oncol. 2023; DOI: 10.1200/PO.22.00483. PMID: 36996374. 

7. Loehr A, Hussain A, Patnaik A, Bryce A, Castellano D, Font A, Shapiro J, Zhang J, Sautois B, Vogelzang N, Chatta G, Courtney K, Harzstark A, Ricci F, Despain D, Watkins S, King C, Nguyen M, Simmons A, Chowdhury S, Abida W. Emergence of BRCA Reversion Mutations in Patients With Metastatic Castration-Resistant Prostate Cancer After Treatment With Rucaparib. Eur. Urol. 2023; 83(3):200-209. PMID: 36243543. 

8. Labadie B, Morris D, Bryce A, Given R, Zhang J, Abida W, Chowdhury S, Patnaik A. Guidelines for Management of Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. Cancer Manag. Res. 2022; 14 673–686. PMCID: PMC8860352. PMID: 35210863.

9. Chaudagar K*, Landon Brace N*, Solanki A*, Hieromnimon H, Hegerniller E, Li W, Shao Y, Joseph J, Wilkins D, Bynoe K, Li XL, Clohessy J, Ullas S, Karp J & Patnaik A. Cabozantinib unlocks efficient in vivo targeted delivery of neutrophil-loaded nanoparticles into murine prostate tumors. Mol. Cancer Ther. 2021. 20(2):438-449. PMID: 33277441. 

10. Rameshbabu S*, Labadie B*, Argulian A, Patnaik A. Targeting Innate Immunity in Cancer Therapy. Vaccines. 2021; 9(2):138. PMID: 33572196. PMCID: PMC7916062.

11. Ascierto P, Campbell K, Daniele B, Dougan M, Emens L, Formenti S, Janku F, Khleif S, Kirchhoff T, Morabito A, Najjar Y, Odunsi K, Nathan P, Patnaik A, Paulos C, Reinfeld B, Skinner H, Timmerman J, Butterfield L, Puzanov I. Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge” (December 4th-5th, 2019, Naples, Italy). J. Transl. Med. 2021; 19(1):13. PMID: 33407605. PMCID: PMC7789268.  

12. Pienta K, Gorin M, Rowe S, Carroll P, Pouliot F, Probst S, Saperstein L, Preston M, Alva A, Patnaik A, Durack J, Stambler N, Lin T, Jensen J, Wong V, Siegel B, Morris M and OSPREY Study Group. A Phase 2/3 Prospective Multicentre Study of the Diagnostic Accuracy of Prostate-Specific Membrane Antigen (PSMA) PET/CT with ¹⁸F-DCFPyL in Patients with Prostate Cancer (OSPREY). J Urol. 2021; 206:52-61. PMID: 33634707. PMCID: PMC8556578. 

13. Ascierto P, Bifulco C, Ciardiello F, Demaria S, Emens L, Ferris R, Formenti S, Galon J, Khleif S, Kirchhoff T, McQuade J, Odunsi K, Patnaik A, Paulos C, Taube J, Timmerman J, Fox B, Hwu P, Puzanov I. Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy). J Transl. Med. 2021; 19(1):238. PMID: 34078406. PMCID: PMC8173810. 

14. Li Q, Liu K, Liu Q, Wang G, Jiang W, Meng Q, Yi Y, Yang Y, Wang R, Zhu S, Li C, Yan L, Zhang L, Zhao D, Kim J, Zu X, Kozielski A, Qian W, Chang J, Patnaik A, Chen K, Cao Q. Antihistamine Drug Ebastine Inhibits Cancer Growth by Targeting Polycomb Group Protein EZH2. Molecular Cancer Therapeutics. 2020; 19(10):2023-2033. PMID: 32855270.

15. McKay R, Morgans A, Paller C, Antonarkis E, Beer T, Borno H, Carlo M, George D, Graff J, Gupta S, Health E, Higano C, Patnaik A, Petrylak D, Rettig M, Ryan C, Taplin M, Whang Y, Vinson J, Giri V, Cheng H; PCCTC Germline Genetics Working Group. Current Guidelines, Practical Considerations and Challenges for Germline Genetic Testing in Prostate Cancer Patients. Journal of Oncology Practice. 2020; 17(4):275- 282. PMID: 32986533. PMCID: PMC6662206.

16. Abida W, Campbell D, Patnaik A, Shapiro J, Sautois B, Vogelzang N, Voog E, Bryce A, McDermott R, Ricci F, Rowe J, Zhang J, Piulats J, Fizazi K, Merseberger A, Higano C, Krieger L, Ryan C, Feng F, Simmons A, Loehr A, Despain D, Dowson M, Green F, Watkins S, Golsorkhi T, Chowdhury S. Non-BRCA DNA damage repair gene alterations and response to the PARP inhibitor rucaparib in metastatic castration-resistant prostate cancer. Clin. Cancer Res. 2020; 26(11):2487-2496. PMID 32086346. 

17. Kather J, Heij L, Grabsch H, Loeffler C, Echle A, Krause J, Muti H, Niehuis J, Sommer J, Bankhead P, Schulte J, Cipriani N, Ortiz-Brüchle N, Paner G, Patnaik A, Jäger D, Trautwein C, Van den Brandt P, Kooreman L, Pearson A, Luedde T. Pan-cancer image-based genetic testing. Nat Cancer. 2020; (1):789-799. PMID: 33763651. PMCID: PMC7610412. 

18. Abida W, Patnaik A, Campbell D, Shapiro J, Bryce A, McDermott R, Sautois B, Vogelzang N, Bambury R, Voog E, Zhang J, Piulats J, Ryan C, Merseburger A, Daugaard Heidenreich A, Fizazi K, Higano C, Krieger L, Sternberg C, Watkins S, Despain D, Simmons A, Loehr A, Dowson M, Golsorkhi T, Chowdhury, S. Rucaparib in men with metastatic castration-resistant prostate cancer harboring a BRCA1 or BRCA2 gene alteration. J. Clin. Oncol. 2020; 38:3763-3772. PMID: 32795228. 

19. Sharma P, Pachynski R, Narayan V, Fléchon A, Gravis G, Galsky M, Mahammedi H, Patnaik A, Subudhi S, Ciprotti M, Simsek B, Saci A, Hu Y, Han G, Fizazi K. Nivolumab Plus Ipilimumab for Metastatic Castration-Resistant Prostate Cancer: Preliminary Analysis of Patients in the CheckMate 650 Trial. Cancer Cell. 2020; 38(4):489-499. PMID: 32916128.

20. Paller C, Antonarkis E, Beer T, Borno H, Carlo M, George D, Graff J, Gupta S, Health E, Higano C, McKay R, Morgans A, Patnaik A, Petrylak D, Rettig M, Ryan C, Taplin M, Whang Y, Vinson J, Cheng H, Giri V; PCCTC Germline Genetics Working Group.  Germline Genetic Testing in Advanced Prostate Cancer; Practices and Barriers: Survey Results from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. Clin. Genitourin. Cancer. 2019; (4):275-282. PMID: 31171481. PMCID: PMC6662206.

21. Olson B, Patnaik A. Utilizing Precision Medicine to Modulate the Prostate Tumor Microenvironment and Enhance Immunotherapy. Urol. Oncol. 2018; S1078-1439 (18) 30455-1. PMID: 30503851. 

22. Olson B, Liu E, Patnaik A. Co-clinical trials of Novel Immuno-Oncology combination therapies in mouse models of cancer. Cancer Discov. 2018; 8(11): 1358-1365. PMID: 30309862

23. Carlo M, Giri V, Antonarakis E, Abida W, Alumkal J, Beer T, Beltran H, George D, Heath E, Higano C, McKay R, Morgans A, Patnaik A, Ryan C, Schaeffer E, Stadler W, Taplin M, Kauff N, Paller C, Vinson J, Cheng H. Evolving Intersection between Inherited Cancer Genetics and Therapeutic Clinical Trials in Prostate Cancer: A White Paper from the Germline Genetics Working Group of the Prostate Cancer Clinical Trials Consortium. JCO Precis. Oncol. 2018; 1:1-14. PMID: 30761386.

24. Patnaik A, Swanson KD, Csizmadia E, Solanki A, Landon-Brace N, Gehring M, Helenius K, Olson BM, Pyzer AR, Wang LC, Elemento O, Novak J, Thornley TB, Asara JM, Montaser L, Timmons JJ, Morgan TM, Wang Y, Levantini E, Clohessy JG, Kelly K, Pandolfi PP, Rosenblatt JM, Avigan DE, Ye H, Karp JM, Signoretti S, Balk SP and Cantley LC. Cabozantinib eradicates advanced murine prostate cancer by activating anti-tumor innate immunity. Cancer Discov. 2017; 7(7):750-765. PMID: 28274958.

25. Sturey B, Patnaik A. Neutrophils and Anti-cancer Immunity: A Paradigm Shift in Cancer Immunotherapy. Oncoscience. 2017; 4(11-12): 164-165. PMID: 29344550.

26. Li Y, Malapati S, Lin Y, Patnaik A. An integrative approach for sequencing therapies in metastatic castrate-resistant prostate cancer. Am. J. Hematol. Oncol. 2017; 13 (12): 26-31.

27. Gao S, Ye H, Gerrin S, Wang H, Sharma A, Chen S, Patnaik A, Sowalsky AG, Voznesensky O, Han W, Yu Z, Mostaghel E, Nelson PS, Taplin ME, Balk SP, Cai C. ErbB2 Signaling Increases Androgen Receptor Expression in Abiraterone-Resistant Prostate Cancer. Clin. Cancer Res. 2016; 22(14):3672-82. PMID: 26936914. 

28. González-Billalabeitia* E, Seitzer N* (co-first author), Song SJ, Song MS, Patnaik A, Liu XS, Epping MT, Papa A, Hobbs R, Chen M, Lunardi A, Webster KA, Signoretti S, Loda M, Asara J, Nardella C, Cantley LC, Pandolfi PP. p53 Status Dictates Differential Response to PARP inhibition upon PTEN-loss. Cancer Discov. 2014; 4(8): 896-904. PMID: 24866151.

29. Lunardi A, Nardella C, Ala U, Salmena L, Webster KA, Wang G, Lis R, Stack EC, Patnaik A, Wong KK, Engelman JA, Cantley LC, Bubley G, Gerald WL, Montironi1 R, Signoretti S, Loda M, Pandolfi PP. “Co-Clinical” identification of novel genetic determinants and molecular mechanisms underlying prostate cancer resistance to androgen deprivation. Nat. Genet. 2013; 45(7):747-755. PMID: 23727860. 

30. Fendt S, Bell E, Keibler M, Davidson M, Wirth G, Fiske B, Mayers J, Patnaik A, Bellinger G, Csibi A, Blenis J, Cantley L, Guarente L, Pollak M, Olumi A, Vander Heiden M, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. Cancer Res. 2013; 73:4429-4438. PMID: 23687346. 

31. Nardella C, Lunardi A, Patnaik A, Cantley LC, Pandolfi PP. The APL Paradigm and the “Co-Clinical Trial” Project. Cancer Discov. 2011; 1:108-116. PMCID: PMC3222327. 

32. Giorgia Z, Carmen P, Patnaik A, Loda M. New strategies in Prostate Cancer: Targeting Lipogenic Pathways and the Energy Sensor AMPK. Clin. Cancer Res. 2010; 16(13): 3322-3328. PMCID: PMC3176306.

33. Shaywitz AJ*, Courtney KD*, Patnaik A*, Cantley LC (*Equal contribution). PI3K Enters Beta Testing. Cell Metab. 2008; 8:179-181. PMCID: PMC3389549.